VC
Vivo Capital Portfolio holdings
AUM
$977M
1-Year Return
209.68%
This Quarter Return
+32.03%
1 Year Return
+209.68%
3 Year Return
+1,480.07%
5 Year Return
+2,591.98%
10 Year Return
–
AUM
$977M
AUM Growth
+$222M
(+29%)
Cap. Flow
+$76.9M
Cap. Flow
% of AUM
7.87%
Top 10 Holdings %
Top 10 Hldgs %
75%
Holding
45
New
5
Increased
5
Reduced
5
Closed
3
Top Buys
| 1 |
SVA
Sinovac Biotech, Ltd
SVA
|
+$38.2M |
| 2 |
Cidara Therapeutics
CDTX
|
+$30.5M |
| 3 |
CytomX Therapeutics
CTMX
|
+$13.1M |
| 4 |
Akero Therapeutics
AKRO
|
+$12.5M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$10.6M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
+$41.9M |
| 2 |
Instil Bio
TIL
|
+$6.1M |
| 3 |
RGLS
Regulus Therapeutics
RGLS
|
+$4.72M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$4.29M |
| 5 |
Delcath Systems
DCTH
|
+$2.46M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Soleno Therapeutics
SLNO
$3.19B
| $332M | 33.94% |
3,958,294
-500,000
| -11% | -$41.9M |
|
|
VRNA
2
Verona Pharma
VRNA
$9.2B
| $132M | 13.49% |
1,393,432
-45,353
| -3% | -$4.29M |
|
|
3
Cidara Therapeutics
CDTX
$1.61B
| $63.9M | 6.54% |
1,311,425
+627,149
| +92% | +$30.5M |
|
4
Geron
GERN
$823M
| $38.4M | 3.93% |
27,225,292
| – | – |
|
|
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
| $38.2M | 3.91% |
+5,903,000
| New | +$38.2M |
|
|
6
Oric Pharmaceuticals
ORIC
$1.02B
| $31.7M | 3.25% |
3,126,604
+1,046,154
| +50% | +$10.6M |
|
7
Terns Pharmaceuticals
TERN
$654M
| $25.7M | 2.63% |
6,895,746
| – | – |
|
8
Trevi Therapeutics
TRVI
$1.17B
| $24.5M | 2.51% |
4,487,903
+1,000,000
| +29% | +$5.47M |
|
|
AVDL
9
Avadel Pharmaceuticals
AVDL
$1.54B
| $23.8M | 2.43% |
2,684,109
| – | – |
|
|
10
Akero Therapeutics
AKRO
$3.46B
| $23.2M | 2.37% |
434,689
+233,521
| +116% | +$12.5M |
|
11
Compass Therapeutics
CMPX
$604M
| $15.7M | 1.61% |
6,043,466
+2,487,443
| +70% | +$6.47M |
|
12
Viridian Therapeutics
VRDN
$1.62B
| $13.7M | 1.41% |
982,576
| – | – |
|
|
13
CytomX Therapeutics
CTMX
$341M
| $13.1M | 1.34% |
+5,769,230
| New | +$13.1M |
|
14
Aclaris Therapeutics
ACRS
$221M
| $12.6M | 1.29% |
8,888,888
| – | – |
|
|
ZBIO
15
Zenas BioPharma, Inc. Common Stock
ZBIO
$833M
| $11.5M | 1.17% |
1,183,260
| – | – |
|
16
Dyne Therapeutics
DYN
$1.89B
| $10.6M | 1.09% |
1,114,960
| – | – |
|
17
Abeona Therapeutics
ABEO
$335M
| $10.5M | 1.07% |
1,842,751
| – | – |
|
|
DBVT
18
DBV Technologies
DBVT
$260M
| $9.66M | 0.99% |
+1,054,506
| New | +$9.66M |
|
19
Tourmaline Bio
TRML
$1.22B
| $9.46M | 0.97% |
591,882
| – | – |
|
20
Rezolute
RZLT
$705M
| $9.42M | 0.96% |
2,112,432
| – | – |
|
|
CMPS
21
Compass Pathways
CMPS
$485M
| $9.41M | 0.96% |
3,362,385
| – | – |
|
22
Corvus Pharmaceuticals
CRVS
$442M
| $8.94M | 0.91% |
2,234,566
| – | – |
|
23
Erasca
ERAS
$440M
| $8.58M | 0.88% |
6,756,756
| – | – |
|
24
IO Biotech
IOBT
$117M
| $8.58M | 0.88% |
6,173,439
| – | – |
|
25
Astria Therapeutics
ATXS
$423M
| $8.32M | 0.85% |
1,552,685
| – | – |
|